Huub H van Rossum,Stefan Holdenrieder
Huub H van Rossum
Clinical laboratories are responsible for performing lung cancer tumor marker testing as part of routine clinical care. It is their responsibility to guarantee that the reported tumor marker results are reliable and meet the necessary quali...
Lung cancer biomarkers: Raising the clinical value of the classical and the new ones [0.03%]
肺癌生物标志物：提高传统及新型生物标志物的临床价值
Stefan Holdenrieder,Huub H van Rossum,Michel van den Heuvel
Stefan Holdenrieder
Blood-based diagnostics for lung cancer support the diagnosis, estimation of prognosis, prediction, and monitoring of therapy response in lung cancer patients. The clinical utility of serum tumor markers has considerably increased due to de...
Factors influencing blood tumor marker concentrations in the absence of neoplasia [0.03%]
非肿瘤状态下影响血液肿瘤标志物浓度的因素分析
Jaume Trapé,Esther Fernández-Galán,Josep Maria Auge et al.
Jaume Trapé et al.
Background: Tumor markers (TMs) are a heterogeneous group of molecules used in the diagnosis, prognosis and follow-up of cancer patients. During neoplastic differentiation, cells can either directly synthesize or induce t...
Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy [0.03%]
肿瘤标志物对非小细胞肺癌患者预后和预测治疗反应的相关性：CEPAC-TDM生物标志物分研究
Kimberly Geiger,Markus Joerger,Max Roessler et al.
Kimberly Geiger et al.
Background: Protein tumor markers are released in high amounts into the blood in advanced non-small cell lung cancer (NSCLC). Objective: ...
Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations [0.03%]
利用多种蛋白质肿瘤标志物组合提高肺癌鉴别诊断的效果
Inga Trulson,Frank Klawonn,Joachim von Pawel et al.
Inga Trulson et al.
Background: Differential diagnosis of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in hospitalized patients is crucial for appropriate treatment choice. ...
Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy - A CEPAC-TDM biomarker substudy [0.03%]
可溶性PD-1、PD-L1和PD-L2在化疗肺癌患者中的预后价值缺失 - 一项CEPAC-TDM生物标志物子研究
Kimberly Geiger,Markus Joerger,Max Roessler et al.
Kimberly Geiger et al.
Background: Programmed cell death receptors and ligands in cancer tissue samples are established companion diagnostics for immune checkpoint inhibitor (ICI) therapies. ...
The p110α/ΔNp63α complex mutations in triple-negative breast cancer: Potential targets for transcriptional-based therapies [0.03%]
三阴性乳腺癌中p110α/ΔNp63α复合体突变：基于转录的疗法潜在靶标
Wenqiong Ma,Xingping Han,Marzieh Dehghan Shasaltaneh et al.
Wenqiong Ma et al.
Background: Hotspot mutations occurring in the p110α domain of the PIK3CA gene, specifically p110αH1047R/L increase tumor metastasis and cell motility in triple-negative breast cancer (TNBC). These mutations also affect...
The effects of ALK5 inhibition and simultaneous inhibition or activation of HIF-1α in melanoma tumor growth and angiogenesis [0.03%]
ALK5抑制以及同时抑制或激活HIF-1α对黑色素瘤肿瘤生长和血管生成的影响
Bahareh Zarin,Reza Nedaeinia,Ismail Laher et al.
Bahareh Zarin et al.
Background: Hypoxia is the most common signature of the tumor microenvironment that drives tumorigenesis through the complex crosstalk of a family of transcription factors called hypoxia-inducible factors (HIFs), with oth...
Circulating lung cancer biomarkers: From translational research to clinical practice [0.03%]
循环肺癌生物标志物：从转化研究到临床实践
Xu Qian,Qing-He Meng
Xu Qian
Fundamental studies on biomarkers as well as developed assays for their detection can provide valuable information facilitating clinical decisions. For patients with lung cancer, there are established circulating biomarkers such as serum pr...
Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008-2022 update [0.03%]
基于血液的蛋白生物标志物在非小细胞肺癌预后中的价值：批判性回顾与2008-2022年更新
Inga Trulson,Stefan Holdenrieder
Inga Trulson
Background: Therapeutic possibilities for non-small cell lung cancer (NSCLC) have considerably increased during recent decades. Objective: ...